

APBMT Annual Report Fiscal 2018

Asia-Pacific Blood and Marrow Transplantation Group
SECRETARIAT OFFICE / DATA CENTER OF APBMT





**Asia-Pacific Blood and Marrow
Transplantation Group
(APBMT)**

Annual Report

Fiscal 2018

Secretariat Office / Data Center of APBMT

E-mail: office@apbmt.org

Website: <http://www.apbmt.org>

Contents

Introduction

General overview for the last year	1
Organizational tree	2
Principal members	3
Annual Meetings	4
Number of attendees for each annual meeting	6

Activity Survey

Introduction of the Activity Survey	8
---	---

Outcome Registry

About the Outcome Registry	9
Registry Committee member list	10

Executive Board

Key activities and member list	11
--------------------------------------	----

Collaboration with Other International Registries

General Information	12
History of International Scientific Symposia	13

Blood Cell Therapy -The Official Journal of APBMT-

About the journal-----	17
Editorial Board member list -----	18
Manuscript submission rules for Authors	19
Editorial Policies	28
Guide for Reviewers	33
List of the accepted articles	37

Appendix

Offering Delta Mileage to medical professionals in emerging countries	41
Sponsorship-----	44

Introduction

General overview from September 2018 to August 2019

Nepal joined APBMT in the fiscal 2018 and we are comprised of 22 countries/regions as of August 2019:


Australia
Bangladesh
Cambodia
China
Hong Kong
India
Indonesia
Iran
Japan
Korea
Malaysia
Mongolia
Myanmar
Nepal
New Zealand
Pakistan
Philippines
Singapore
Sri Lanka
Taiwan
Thailand
Vietnam



This Annual Report is the 11th edition. This edition includes a lot of information regarding the fiscal 2018 of APBMT (from September 2018 to August 2019). Because the Registry Committee decided to change the schedule of Activity Survey data collection according to the WBMT research guidelines at the in-person meeting in Taiwan on November 2nd 2018, this booklet includes results of the 12th and 13th Activity Survey (transplantations performed in 2016 and 2017).

Since APBMT launched our official e-journal, Blood Cell Therapy, on October 17th 2017, Editorial Office has received 25 submissions as of the end of August 2019. The first issue was published on October 28, 2018 (the early edition on our website) and the journal is being published periodically.

Organizational tree of APBMT



Principal member list (Aug.2019)

Executive Board members

Shinichiro Okamoto (Chairman, Japan)	Alok Srivastava (Vice-chair, India)	David D Ma (Australia/New Zealand)
He Huang (China)	Amir Ali Hamidieh (Iran)	Jong Wook Lee (Korea)
William YK Hwang (Singapore)		

*Scientific Committee Members (*Executive Board members)*

Yoshiki Akatsuka (Japan)	Otgonbat Altangerel (Mongolia)	Shashikant Apte (India)
Khishigjargal Batsukh (Mongolia)	Carmella Bingcang (Philippines)	Udomsak Bunworasate (Thailand)
Po-Min Chen (Taiwan)	Phu Chi Dung (Vietnam)	Tzeon-Jye Chiou (Taiwan)
Lallindra Gooneratne (Sri Lanka)	Aye Aye Gyi (Myanmar)	Amir Ali Hamidieh (Iran) *
Suradej Hongeng (Thailand)	He Huang (China) *	Xiao-Jun Huang (China)
Tai-ju Hwang (Korea)	William YK Hwang (Singapore) *	Hyoung Jin Kang (Korea)
Mohiuddin Khan (Bangladesh)	Navin Khattry (India)	Bor-Sheng Ko (Taiwan)
Mickey Koh (Singapore)	Hoon Kook (Korea)	Jong Wook Lee (Korea) *
Albert Lie (Hong Kong)	Kai-Hsin Lin (Taiwan)	Kai-yan Liu (China)
David D Ma (Australia/New Zealand) *	Ming Yao (Taiwan)	Koichi Miyamura (Japan)
Shinichiro Okamoto (Japan) *	Jian Ouyang (China)	Pheng Bora (Cambodia)
Philip Rowlings (Australia/New Zealand)	Tahir Sultan Shamsi (Pakistan)	Alok Srivastava (India) *
Jih-Luh Tang (Taiwan)	Shuichi Taniguchi (Japan)	Takanori Teshima (Japan)
Artit Ungkanont (Thailand)	Auro Viswabandya (India)	Jianmin Wang (China)
Jong-Ho Won (Korea)	Tong Wu (China)	Mei Zhang (China)

Past-Scientific Committee members

Kamran Alimoghaddam (Iran)	Honorata G Baylon (Philippines)	George Biju (India)
Mammen Chandy (India)	Yao-Chang Chen (Taiwan)	Lin Haipeng (Malaysia)
Mine Harada (Japan)	Herman Hariman (Indonesia)	Jun Ling Hong (China)
Dong-Wook Kim (Korea)	Hack-Ki Kim (Korea)	Seiji Kojima (Japan)
Hong Hoe Koo (Korea)	Raymond Liang (Hong Kong)	Mohammadreza Ostadali Dehaghi (Iran)
Hee Young Shin (Korea)	Alan Teh (Malaysia)	Van Binh Tran (Vietnam)
Cheng-Hwai Tzeng (Taiwan)	Mathews Vikram (India)	

Honorary Members

Kerry Atkinson (Australia)	John Carter (New Zealand)	Dennis Confer (NMDP)
John Goldman (EBMT)	Alois Gratwohl (EBMT)	Geoffrey Hill (Australia)
Mary Horowitz (CIBMTR)	Dietger Niederwieser (EBMT)	

Emeritus Members

Suresh H Advani (India)	Shigetaka Asano (Japan)	Lu Xian Cao (China)
Ardeshtir Ghavamzadeh (Iran)	Surapol Issaragrisil (Thailand)	Saengsuree Jootar (Thailand)
Chun Choo Kim (Korea)	Dong Jip Kim (Korea)	Yoshihisa Koderia (Japan)
Dao-Pei Lu (China)	Tohru Masaoka (Japan)	Tan Binh Nguyen (Vietnam)
Tapan K Saikia (India)	Pattic Tan (Singapore)	

Annual Meetings of APBMT

Previous Meetings

No	Year	City	President
1 st	1990	Beijing	Lu Xian Cao
2 nd	1991	Nagoya	Tohru Masaoka
3 rd	1992	Osaka	Tohru Masaoka
4 th	1994	Fukuoka	Tohru Masaoka
5 th	1996	Seoul	Dong Jip Kim
6 th	1998	Taipei	Yao-Chang Chen
7 th	2000	Bangkok	Surapol Issaragrisil
8 th	2002	Mumbai	Suresh Advani
9 th	2004	Tehran	Ardeshir Ghavamzadeh
10 th	2005	Hangzhou	Dao-Pei Lu
11 th	2006	Nagoya	Yoshihisa Kodera
12 th	2007	Beijing	Dao-Pei Lu
13 th	2008	Taipei	Po-Min Chen
14 th	2009	Seoul	Chun-Choo Kim
15 th	2010	Phuket	Saengsuree Jootar
16 th	2011	Sydney	David Ma / Philip Rowlings
17 th	2012	Hyderabad	Tapan K Saikia / Alok Srivastava
18 th	2013	Ho Chi Minh City	Tan Binh Nguyen
19 th	2014	Hangzhou	He Huang / Xiaojun Huang
20 th	2015	Okinawa	Shinichiro Okamoto
21 th	2016	Singapore	William YK Hwang / Chng Wee Joo / Aloysius Ho
22 nd	2017	Tehran	Ardeshir Ghavamzadeh
23 rd	2018	Taipei	Ming Yao / Jih-Luh Tang
24 th	2019	Busan	Jong Wook Lee / Jong-Ho Won

Future Meetings

- The 25th meeting
October 9 –11, 2020, Kochi, India
Congress President: Mammen Chandy
Scientific Chair: Navin Khattry
Committee Chair: Alok Srivastava
- The 26th meeting
4th Week of October 2021, Chang Mai, Thailand
Congress President: Artit Ungkanont
Scientific Chair: Suradej Hongeng
Scientific co-Chair: Udmsak Bunworasate

The number of attendees for each annual meeting from 2008 to 2019

2008(TAIWAN)		2009(KOREA)		2010(THAILAND)		2011(AUSTRALIA/N EW ZEALAND) ※		2012(INDIA)		2013(VIETNAM)	
Taiwan	349	Korea	292	Thailand	280	Australia	637	India	118	Vietnam	375
Korea	46	China	65	China	100	China	178	China	66	China	82
Japan	24	Taiwan	34	Taiwan	63	New Zealand	84	Japan	19	Korea	41
Malaysia	6	Japan	33	Korea	52	Korea	57	Korea	15	Japan	32
Thailand	5	Thailand	19	Japan	25	Japan	38	Vietnam	12	Taiwan	17
Australia	5	Australia	7	Singapore	19	Taiwan	16	Australia	11	Thailand	13
Pakistan	3	Viet Nam	5	Malaysia	17	Malaysia	14	Germany	8	Hong Kong	7
Hong Kong	3	USA	4	Hong Kong	13	Singapore	14	Taiwan	7	Belgium	6
Singapore	3	Germany	3	Vietnam	13	Thailand	12	Iran	6	Singapore	6
USA	2	Singapore	2	Australia	9	Vietnam	10	USA	6	France	5
Saudi Arabia	2	France	1	Iran	8	Philippines	9	Singapore	4	India	5
Philippines	2	Hong Kong	1	Italy	6	India	6	Philippines	3	Australia	4
India	1	Indonesia	1	Germany	4	Hong Kong	5	Bangladesh	2	Iran	4
Vietnam	1	Iran	1	Indonesia	4	Myanmar	4	Belgium	2	United States	4
Romania	1	Malaysia	1	USA	4	Switzerland	4	France	2	Germany	3
France	1	Philippines	1	India	3	Bangladesh	3	Hong Kong	2	Mongolia	3
Total	454	Switzerland	1	Pakistan	3	Pakistan	3	Mongolia	2	Spain	3
	%	UK	1	France	2	Fiji	2	Canada	1	Malaysia	2
Domestic	77	Total	472	Myanmar	2	Samoa	2	Italy	1	Philippines	2
Foreign	23		%	Canada	1	UAE	2	Myanmar	1	Indonesia	1
		Domestic	62	Hungary	1	Brunei	1	Nepal	1	Ireland	1
		Foreign	38	Israel	1	Cook Islands	1	Sweden	1	Myanmar	1
				Philippines	1	Indonesia	1	UK	1	Netherlands	1
				Sweden	1	Iran	1	Missing	3	Sweden	1
				Turkey	1	Israel	1	Total	294	UK	1
				Total	633	Kiribati	1		%	Total	736
					%	Micronesia	1	Domestic	40		%
				Domestic	44	Papua New Guinea	1	Foreign	60	Domestic	61
				Foreign	56	Slovak Republic	1			Foreign	40
						Slovakia	1				
						Solomon Islands	1				
						Sri Lanka	1				
						Turkey	1				
						Tuvalu	1				
						Vanuatu	1				
						Total	1115				
							%				
						Domestic	65				
						Foreign	35				

※APBMT 2011 with HAA-ISHAPD 2011 and ISCTA

※※APBMT 2019 with ICBMT 2019

2014(CHINA)		2015(JAPAN)		2016(SINGAPORE)		2017(IRAN)		2018(Taiwan)		2019(Korea) ※ ※	
China	646	Japan	159	Singapore	234	Iran	565	Taiwan	330	Korea	762
Japan	31	China	186	China	116	China	32	China	90	China	125
Taiwan	24	Taiwan	51	Japan	62	USA	4	Japan	66	Japan	47
Korea	16	Korea	41	Korea	44	Germany	4	Korea	33	Taiwan	46
United States	11	Singapore	23	Taiwan	28	Japan	3	Singapore	32	India	37
India	9	Hong Kong	17	India	25	Thailand	3	Vietnam	29	Indonesia	22
Singapore	9	Vietnam	16	USA	22	Qatar	3	Thailand	21	Singapore	22
Australia	7	India	11	Thailand	21	France	2	Hong Kong	18	Malaysia	17
Mongolia	7	Thailand	11	Hong Kong	19	Italy	2	USA	15	USA	17
UK	5	Indonesia	9	Malaysia	19	Belgium	1	Philippines	13	Vietnam	16
Hong Kong	4	USA	7	Bangladesh	15	India	1	India	11	Germany	11
Philippines	4	Malaysia	6	Vietnam	15	Turkey	1	Malaysia	8	Hong Kong	10
Vietnam	4	Australia	5	Australia	13	UK	1	Indonesia	7	Thailand	9
France	3	Philippines	5	Iran	11	Malaysia	1	Australia	6	Iran	8
Iran	3	UK	4	Philippines	10	Sri Lanka	1	Bangladesh	6	Mongolia	8
Thailand	3	Germany	2	Germany	9	Switzerland	1	Sri Lanka	5	Pakistan	8
Germany	2	Iran	2	Sri Lanka	6	Total	625	UK	5	Philippines	7
Myanmar	2	Sri Lanka	2	UK	6		%	Germany	4	Australia	5
Pakistan	2	Bangladesh	1	France	4	Domestic	90	Canada	3	Egypt	3
Bangladesh	1	Cambodia	1	Mongolia	4	Foreign	10	Mongolia	3	France	3
Indonesia	1	Canada	1	Indonesia	3			Myanmar	3	Turkey	3
Lebanon	1	France	1	Ireland	3			Romania	2	UK	3
Malaysia	1	Italy	1	Italy	3			Cambodia	1	Switzerland	2
South Africa	1	Mongolia	1	Cambodia	2			France	1	Spain	2
Spain	1	Myanmar	1	Myanmar	2			Iran	1	Bangladesh	2
Sri Lanka	1	Pakistan	1	Qatar	2			Netherlands	1	Austria	1
Total	799	Switzerland	1	Belgium	1			North Korea	1	Brazil	1
	%	Missing	1	Canada	1			Spain	1	Cambodia	1
Domestic	81	Total	567	Nepal	1			Total	716	Canada	1
Foreign	19		%	New Zealand	1				%	Italy	1
		Domestic	28	Spain	1			Domestic	46	Myanmar	1
		Foreign	72	Switzerland	1			Foreign	54	Nepal	1
				Total	704					Netherlands	1
					%					Poland	1
				Domestic	33					Sri Lanka	1
				Foreign	67					Uzbekistan	1
										Total	1206
										%	
										Domestic	63
										Foreign	37

Activity Survey

Introduction of Activity Survey

The APBMT Activity Survey has been performed annually from 2007 (HSCT data from 2005). This survey is a collection of the number of transplantations sorted by the donors' sources and diseases in each country/region.

The following figure shows how the data is collected.




Figure: Data collection

The method of submission is different in each country/region.

As shown in the Figure above, data from China, India, Japan, Korea, Malaysia, and Taiwan was submitted through their national registry. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) submitted the national data for Australia and New Zealand. In Bangladesh, Iran, Mongolia, Myanmar, Nepal, the Philippines, Sri Lanka, and Thailand data was collected by a particular contact person and submitted to Data Center. Data Center has direct contact with major transplantation centers and receives data from Hong Kong, Pakistan, Singapore, and Vietnam. Data Center compiles all data collected in each of these 4 countries/regions, and compiled data is available for each country/region to use as national data.

The aim of the 12th and 13th APBMT Activity Survey is to update **the HSCT activities in 2016 and 2017** in this region. Data Center received data from 20 countries/regions by December 31, 2019.

Outcome Registry

About Outcome Registry

APBMT launched Outcome Registry in July 2010. APBMT Outcome Registry forms are called the “Least Minimum Dataset (LMD)”, which are simplified report forms based on the EBMT MED-A or the CIBMTR TED, made by the APBMT Data Center. The countries/regions started reporting HSCT outcome data - transplantations performed in 2010 or 2011 (limited data from 2009 was also available) - using the LMD forms according to each country/region’s situation. In February 2011, APBMT Data Center started to receive HSCT outcome data from CIBMTR through data transfer agreements, which were established between APBMT and CIBMTR and between APBMT and some centers that submitted Outcome Data to CIBMTR.

To promote and accelerate the data collection, APBMT decided to establish the Registry Committee in October 2014. The Committee officially started operations in October 2015, and since then, it has held web conferences bimonthly. In this fiscal year, the Committee approved two documents: The Committee terms and the Detailed rules for data usage and authorship.

REDCap-SaaS 4010-0001 アジア太平洋造血細胞移植学会
APBMT Outcome Registry

Record Home Page

The grid below displays the form-by-form progress of data entered for the currently selected record. You may click on the colored status icons to access that form/event.

Choose action for record: [v]

Record ID: 5640010 Date of 1st HSCT = 2020
5640010 Blood Transfusion Hematology Hospital

Data Collection Instrument	Registered Year Date of 1st HSCT =	2020	-- archived	2019
Day100				
Disease				
Follow Up				

Repeating Instruments

Follow Up 2019

1 [red icon] Date of follow-up data entry = [v]
+ Add new

Legend for status icons:

- Incomplete (red circle with exclamation mark)
- Incomplete (no data saved) (yellow circle with exclamation mark)
- Unverified (yellow circle with question mark)
- Complete (green circle with checkmark)
- Many statuses (all same) (yellow circle with multiple colored dots)
- Many statuses (mixed) (blue circle with multiple colored dots)

Registry Committee and Data Center has established the electronic data capture (EDC) system using REDCap® in this fiscal year and started outcome data collection. By using this system, we expect that data managers will be freed from their burden of data submission and data capture rate will improve.

On behalf of the Registry Committee, Iida and the members of this committee submitted a paper regarding HSCT activities from 2005 to 2015 in the Asia-Pacific region and it was accepted in Bone Marrow Transplantation on May 14, 2019.

Registry Committee member list

	Name	Country/Region
Chairperson	Yoshiko Atsuta	Japan
Deputy Chairpersons	Anthony Dodds	Australia/New Zealand
	Aloysius Ho	Singapore
Members	Mafruha Akter	Bangladesh
	Pheng Bora	Cambodia
	Xiao Jun Huang	China
	Liu Kaiyan	China
	Joycelyn Sim	Hong Kong
	Alok Srivastava	India
	Kavitha M.L	India
	Damai Santosa	Indonesia
	Amir Hamidieh	Iran
	Shinichiro Okamoto	Japan
	Yachiyo Kuwatsuka	Japan
	Joon Ho Moon	Korea
	Kim Wah Ho	Malaysia
	Batsukh Khishigjargal	Mongolia
	Aye Aye Gyi	Myanmar
	Tasneem Farzana	Pakistan
	Marjorie Rose Bravo	Philippines
	Prasad Abeysinghe	Sri Lanka
	Devinda Jayathilake	Sri Lanka
	Bor-Sheng Ko	Taiwan
	Hui-Fen Chiang	Taiwan
	Po-Nan Wang	Taiwan
	Ming Yao	Taiwan
	Artit Ungkanont	Thailand
	Huynh Van Man	Vietnam
Data Center	Minako Iida	Japan
	Yukari Nakao	Japan
	Hiroe Namizaki	Japan

Executive Board

Executive Board members

Name	Country/Region
Shinichiro Okamoto (Chairman)	Japan
Alok Srivastava (Vice Chairman)	India
Amir Hamidieh	Iran
David Ma	Australia
Jong-Wook Lee	Korea
William Hwang	Singapore
He Huang	China

*random order

Key activities

Executive Board members had 11 monthly official web conferences (GoToMeeting®) from September 2018 to August 2019, and members also had many ad-hoc web conferences as needed. The main topics discussed by Executive Board in fiscal 2018 were:

- Working together with local organizing committees to prepare for each annual meeting
- An office-centered organizational approach for hosting the annual meeting
- Amendment of the Bylaws and changing the membership categories
- Establishment of the Center Standards for HSCT and cellular therapy in Asia-Pacific countries/regions with FACT/JACIE
- Education/training of physicians/nurses involved in HSCT and cell therapy
- Collaboration with ASTCT, EBMT, WBMT, and other related Societies in the HSCT field

**Collaboration with
Other International Registries**

WBMT

ASBMT

EBMT

WBMT (Worldwide Network for Blood & Marrow Transplantation)

APBMT is one of the first founding societies of WBMT and has made great efforts to organize WBMT in collaboration with other member societies such as CIBMTR, EBMT, and WMDA since 2007. In 2011, WBMT had the first Workshop and Scientific Symposium in Hanoi for the development of HSCT in Asia-Pacific countries/regions. After this Workshop, extensive support to establish and operate HSCT was provided by leading countries to advancing countries/regions in this area. On September 19 to 21, 2018, WBMT held the 5th Workshop and Scientific Symposium in Beijing. One of the main topics of this Workshop was “International experience and data sharing to improve access and outcomes of transplantation,” and all attendees recognized the importance of creating the HSCT global outcome registration system.

Since 2014, Dr. Yoshihisa Kodaera (Japan) and Dr. Jeff Szer (Australia) have served as WBMT president, and many members in APBMT have been playing important roles in the Standing Committees. In addition, APBMT Data Center has submitted Activity Survey data every year to contribute to the Global Survey.

ASTCT (American Society for Transplantation and Cellular Therapy)

After exchanging memorandums of understanding for dual membership on August 23, 2018, APBMT and ASTCT implemented the dual membership, and APBMT members who applied for this membership could receive many benefits from ASTCT. APBMT and ASTCT will continue to proceed with the second and third collaboration projects.

EBMT (European Society for Blood and Marrow Transplantation)

With the cooperation of EBMT, APBMT could set up an original booth at the annual meeting for the past few years. APBMT could exhibit the activities and contact with not only registered members but also non-members there. With regard to a project for the establishment of the APBMT Center Standards, we could get informative advice from JACIE members.

History of International Scientific Symposia

2018

November, APBMT (Taiwan)

ASBMT / EBMT / WBMT / APBMT Joint Symposium: Past, Now, and Future of Hematopoietic Stem Cell Transplantation

Co-Chairs: M. Yao, MD; S. Okamoto, MD

- Hematopoietic Stem Cell Transplantation: Where we have come from and where do we go? (J. Gajewski)
- Past, now and future of hematopoietic stem cell transplantation (EBMT prospective) (N. Kroger)
- How does the past predict the future of allogeneic transplantation: lessons for the field? (D. Weisdorf)
- How the APBMT is facing the challenge (S. Okamoto)

September, The 5th WBMT Workshop (Beijing, China)

International Experience and Data Sharing to Improve Access and Outcomes of Transplantation

1. Importance of creating the HSCT global outcome registration system
 - Global perspective of HSCT & registration (J Szer)
 - WBMT Global Survey & registration (D Niederwieser)
 - CIBMTR perspective of HSCT and registration (M Pasquini)
 - HSC Donor Registries: Challenges and Perspectives (C Muller)
 - APBMT perspective: Importance of Outcome Data Sharing in Asian Pacific Region (Y Kodaera)
 - Current Activity Survey in the AP region (M Iida)
 - Outcome Registry Current Status and future perspectives (Y Atsuta)
 - Chinese perspective of HSCT and Activity Surveys; Difficulties in Data collection (X Huang)
2. International Standards and Accreditation
 - Steps towards international accreditation: Lessons learned (S Okamoto)
 - Addressing unproven cellular therapies (M Koh)

April, WBMT/AfBMT (Morocco)

First Meeting of the African Blood and Marrow Transplantation Group: SCT in bone marrow failure

Co-Chairs: N. Novitzky, MD; N. Khoubila, MD

- Recent Progress in Diagnosis and Treatment of Inherited Bone Marrow Failure (S. Kojima)

- Acquired (S. Osman Ahmed)

2017

October, APBMT (Iran)

APBMT / WBMT Joint Session: Transplantation reports in the Asian pacific region & the progress of BMT in the world and Asian pacific region

Co-Chairs: A. Ghavamzadeh, MD; S. Okamoto, MD

- The progress of BMT in the Islamic Republic of Iran (A. Ghavamzadeh)
- The report of transplantation in all 15 BMT centers of Iran in the last five years (A. Hajifathali)
- The current status and future challenges of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) (S. Okamoto)
- The history, current status and future trends of WBMT (Y. Kodaera)
- The report of transplantation in China five recent years (H. Huang)
- The advance of HSCT after the enforcement of “The Act for Appropriate Provision of Hematopoietic Stem Cells to be Used in Transplantations” in Japan (Y. Kodaera)
- Outcome of autologous hematopoietic stem cell transplants for multiple myeloma in a single center in Sri Lanka (L. Gooneratne)
- The report of transplantation in Malaysia in five recent years (OT. Chuan)

2016

October, APBMT (Singapore)

WBMT Programme- ASBMT/EBMT/APBMT Joint Session

Co-Chairs: Y. Kodaera, MD; J. Szer, MD

- Future of Hematopoietic Stem Cell Transplantation & Cellular Therapy Modern Conditioning Regimens Prior to allo – HSCT (M. Mohty)
- Hematopoietic Cell Transplant Activity in the United States (CN. Bredeson)
- Design the Future of Hematopoietic Stem Cell Transplantation: APBMT Perspectives (S. Okamoto)
- WBMT – Who Are We, What Have We Done and What Will We Do? (J. Szer)

February, BMT Tandem Meetings

Stem Cell Transplantation for Bone Marrow Failure

Co-Chairs: S. Kojima, MD; SA. Giralt, MD

- Hematopoietic Stem Cell Transplantation in Adult Patients with Acquired Aplastic Anemia: Asian Perspectives (JW. Lee)
- Bone Marrow Failure in Children (S. Kojima)
- Poor Graft Function Post-Transplant – Time to Take this Seriously (SA. Giralt)

2015

October, APBMT (Japan)

Global Trend of HSCT and the Future Role of APBMT (WBMT/APBMT Joint Session (I))

Co-Chairs: Y. Kodera, MD; S. Okamoto, MD

- Medical Products of Human Origin WHO Project: Regulatory Recommendations for MPHO-WBMT (JR. Nunez)
- Global Trends in Hematopoietic Stem Cell Transplantation (HSCT) (D. Niederwieser)
- Starting New HSCT Program in Emerging Countries in Asia-Pacific Area (D. Ma)

Working together with Emerging Countries in HSCT in Asia (WBMT/APBMT Joint Session (II))

Co-Chairs: TK. Saikia, MD; AA. Hamidieh, MD

- Report from Mongolia (B. Khishigjargal)
- Report from Sri Lanka (L. Gooneratne)
- Report from Myanmar (AA. Gyi)
- Report from Indonesia (H. Hariman)
- Report from Philippines (HG. Baylon)
- Report from Bangladesh (MA. Khan)
- Report from Cambodia (B. Pheng)

Future in Hematopoietic Stem Cell Transplantation (ASBMT/EBMT/APBMT Joint Session)

Co-Chairs: S. Okamoto, MD; W. Hwang, MD

- Hematopoietic Cell Transplantation in 2015: How the ASBMT is Facing the Challenges (C. Bredeson)
- Challenges in Hematopoietic Stem Cell Transplantation: The EBMT Perspective (M. Mohty)
- Future of Hematopoietic Stem Cell Transplantation – Asia Pacific perspective (A. Srivastava)

Global Alliance for Nuclear Accident Management in the Field of Hematopoietic Stem Cell Transplantation

Co-Chairs: D. Ma, MD; Y. Kodera, MD

- The Current Status of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) in the Management of Nuclear Accident (D. Ma)

- The Contribution of EBMT to the Global Response of a Large Number of Radiation Victims (R. Pawles)
- Radiation Injury Treatment Network: Hematologists and Oncologists Preparing for a Radiological Disaster (C. Case)

March, EBMT

Innovations in Cancer: A Joint EBMT-EHA-APBMT Session

Co-Chairs: M. Mohty, MD; C. Chomienne, MD; AA. Hamidieh, MD

- New drugs in hematology (M. Mohty)
- Leukemic stem cell heterogeneity: how to monitor and eradicate (C. Chomienne)
- Pediatric HSCT: challenges in the Asia-Pacific region (AA. Hamidieh)

Blood Cell Therapy

The official journal of APBMT



Blood Cell Therapy

The official journal of APBMT

Blood Cell Therapy is the official journal of Asia-Pacific Blood and Marrow Transplantation Group. We have published it since October 2018 and issue quarterly.



Blood Cell Therapy
The official journal of APBMT

[Home](#) | [Articles](#) | [Abstracts](#) | [Submit](#) | [Information](#) | [Editorial Board](#)

[Home](#)

Current Issue

Review Article

Expansion of Haematopoietic Stem and Progenitor Cells: Paving the Way for Next-Generation Haematopoietic Stem Cell Transplantation

Sudipto Bari, Paul Chong, William Ying Khoo Hwang

Volume 2 (2019) Issue 4 No.3 Pages 58-67

Submitted: March 29, 2019 Accepted: September 18, 2019 Published online: November 25, 2019
DOI: <https://doi.org/10.31547/bct-2019-004>

Survey Report

Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka

P Abeysinghe, L Morawaka, S Gunasekara, S Suresh, PWGCC Jayathilake, PHSP Udara, PPR Siriwardena, S Milliken, J Moore, DDF Ma

Volume 2 (2019) Issue 4 No.1 Pages 50-53

Submitted: May 29, 2019 Accepted: August 25, 2019 Published online: November 25, 2019
DOI: <https://doi.org/10.31547/bct-2019-007>


News

Dec 27, 2019
Abstract of APBMT 2019 was uploaded.
Abstract of APBMT annual meeting 2019 was uploaded...

Nov 25, 2019
Blood Cell Therapy Vol.2 Issue4 was published.
Blood Cell Therapy vol.2 is issued....

Aug 1, 2019
Blood Cell Therapy Vol.2 Issue3 was published.
Blood Cell Therapy vol.2 is issued....

[Past News](#)



Asia-Pacific Blood and Marrow Transplantation Group

Online ISSN: 2432-7026

Journal homepage: <https://bct.apbmt.org/>

Aims and scope: Blood Cell Therapy is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation and cell therapy. Not only clinical research but also basic research relevant to cell therapy are covered. The scope of our journal encompasses wide variety of clinical or basic topics including:

- Results of trials with new protocols
- Transplant-related complications
- Transplant outcome studies dealing with QOL, psychology, economy or regional characteristics
- Prognostic analysis based on biomarkers
- Translational research
- Transplantation immunology
- Cellular or gene therapy

Editorial Board member list

Name	Commission	Country
Yoshiki Akatsuka	Editor-in-chief	Japan
Shinichiro Okamoto	Chairman of APBMT	Japan
Jeffrey Szer	Associate Editors	Australia
Haowen Xiao		China
Navin Khattry		India
Auro Viswabandya		India
Ayami Yoshimi		Germany /Japan
Satoshi Takahashi		Japan
Junya Kanda		Japan
Tasuo Ichinohe		Japan
Seok-Goo Cho		Korea
Jae Yong Kwak		Korea
Hee-Je Kim		Korea
Mickey Boon Chai Koh		Singapore
David Yeung		Australia
Philip Rowlings		Australia
Mei Zhang		China
Yuqian Sun		China
Alok Srivastava		India
Amir Hamidieh		Iran
Maryam Behfar		Iran
Akio Kohno		Japan
Mahmoud Aljurf		Saudi Arabia
Rupert Handgretinger		Germany
Daniel Weisdorf		USA
Minako Iida	Editorial Office	Japan
Yukari Nakao		Japan
Hiroe Namizaki		Japan

*random order

Manuscript submission rules for Authors

Description

The journal focuses on field of Hematopoietic stem cell transplantation and cell therapies.

Online submission

Blood Cell Therapy has adopted "Scholar One" online submission system, which allows authors to submit papers via the Web.

INTRODUCTION

BLOOD CELL THERAPY is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation. All manuscripts, except reviews, should include solely new data that have not been published elsewhere. Papers deemed to be outside the scope of *BLOOD CELL THERAPY* will be returned to the author without full peer review to avoid protracted review periods. In the case of rejection in which manuscripts are scrutinized by the Editor but not subjected to the review process because they are out of scope or do not meet our standard, the Editorial Board will always make a prompt decision within 20 days of submission.

We ONLY accept manuscripts via our online manuscript submission system. Before submitting a manuscript, authors should consult our Editorial Policies.

The Editorial Board reserves the right to make any corrections to the text in terms of clarity, consistency, integrity, and readability.

HOW TO SUBMIT

All manuscripts should be submitted on the World Wide Web at <https://mc.manuscriptcentral.com/bct>. Full submission instructions are available at this site. First-time users must create an account. There are two Create Account links, found on the top of the page and just below the Log In box. If you forget your username or password, click the "Reset Password" link and enter your e-mail address. Once you have received an e-mail from the system, please follow the instructions to reset your password.

After logging in, step-by-step instructions for submitting a manuscript are available through the submission screens. Manuscripts must be prepared in one of the following electronic formats: Microsoft Word, PowerPoint, or Excel. All files will be automatically converted to PDF format for compatibility irrespective of language. Files such as TIFF, GIF, and JPEG are acceptable formats for figures. For details, follow the step-by-step tutorial for each role by clicking User Tutorials in the Help box on the Home page after logging in.

TYPES OF ARTICLES

BLOOD CELL THERAPY accepts article types listed in the following table for review by the Editorial Board.

ARTICLE TYPE	TITLE	ABSTRACT	WORD LIMIT (EXCLUDING REFERENCES)	TABLES/ FIGURES	REFERENCES
Original Articles	150 characters	400 words	5000 words	Maximum of 8	Maximum of 60
Case Reports	150 characters	250 words	1000 words	Maximum of 2	Maximum of 10
Short Communications	150 characters	250 words	2000 words	Maximum of 2	Maximum of 8
Review Articles	150 characters	250 words	6000 words	Maximum of 8	Maximum of 100
Invited Review Articles	150 characters	250 words	6000 words	Maximum of 8	Maximum of 100
Letters to the Editor	150 characters	N/A	1000 words	Maximum of 2	Maximum of 10
Survey Reports	150 characters	250 words	2000 words	Maximum of 4	Maximum of 10

Original Articles

Manuscripts containing original research in cell therapy with blood cells (See [About Blood Cell Therapy's AIMS AND SCOPE](#)) are considered for publication. Your original article should include the following sections: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments, Authors' Contribution, Conflict of Interest Disclosure, References, and Figure Legends. For size limits of the manuscript, see the table above.

Case Reports

BLOOD CELL THERAPY can accept a limited number of case reports. It is critical that the reports provide new information having an important clinical impact on cell therapies. Simple descriptions of unusual or rare clinical cases without new findings will not be accepted for publication. Your case report should include the following sections: Abstract, Introduction, Case Presentation, Discussion, Acknowledgments, Authors' Contribution, Conflict of Interest Disclosure, References, and Figure Legends. For size limits of the manuscript, see the table above.

Short Communications

Short communications report new observations of sufficient significance. Sections required are the same with original articles, except that the Results and Discussion sections may be combined. For size limits of the manuscript, see the table above.

Review Articles / Invited Review Articles

Review articles on recent developments in cell therapies with blood cells may be submitted, but generally, the *BLOOD CELL THERAPY* Editorial Board will invite contributions from experts in our scope. Review

articles must cover the topic thoroughly and include appropriate references. Please note that review articles will be peer-reviewed before a final decision on publication is made. This article should include the following: Abstract, Acknowledgments, Authors' Contribution, Conflict of Interest Disclosure, References, and Figure Legends. For size limits of manuscripts, see table above.

Letters to the Editor

BLOOD CELL THERAPY welcomes comments on manuscripts published in the journal. These should be addressed to the Editor-in-Chief. The editor reserves the right to edit the letters for clarity and appropriateness. A title is required, but no abstract is necessary. For the limits of the manuscript, see the table above.

Survey report

Reports on nationwide activity or recent progress in the blood and marrow transplantation programs may be submitted as a Survey Report in order to promote the exchange of information. Although scientific analysis of these data might be difficult, authors are encouraged to prepare their manuscript as a research article consisting of the Abstract, Introduction (including purpose and questions to be solved), Methods (e.g., study design, subjects, data collection methods, and data analysis methods), Results, Preliminary Interpretations/Discussion/Conclusions, Future Plans (e.g., what should be done to improve the current level of reporting), and References. A detailed description of cases among the subjects is not necessary; rather, the summary of subjects such as the age (median, range), the disease, its stage, the source of stem cells, and the preconditioning regimens is suitable. For the limits of the manuscript, see the table above.

PREPARATION OF ARTICLES

Original articles must include the following sections. Each section should be separated by three lines. All sections of the manuscript must be double-spaced. Use of abbreviations should be limited for easier comprehension of the article by broader readers. All abbreviations not commonly used must be spelled out at the first appearance in both the abstract and the text.

- Cover letter
- Title page
- Abstract
- Introduction
- Materials and Methods (or Patients and Methods)
- Results
- Discussion
- Acknowledgements (optional)
- Author's Contribution
- Conflict of Interest
- References
- Figure Legends (if applicable)
- Tables (if applicable)

- Figures (if applicable)
- Supplementary information

Cover Letter

The cover letter must state that the manuscript is original and has not been previously published, nor has any substantial part of the manuscript been submitted or published elsewhere. It should also provide the editor with an introduction to the most important or interesting findings in your work.

Title page

The title page should contain (1) a brief and informative title of the paper (no more than 150 characters, including spaces). (2) The full names of all authors and their affiliations. The names and locations of institutions or companies, including departments or laboratories, should be given for all authors. If several institutions are listed on a manuscript, each author's affiliations should be specified with corresponding superscript numbers. (3) A brief running title of no more than 50 characters.

Abbreviations can be used. (4) Three to five keywords that best describe your manuscript. (5) The corresponding author(s) name, full postal address, telephone and fax numbers, and e-mail address. (6) Financial support (if applicable). A disclosure of sources of any support for the author's research, received in the form of grants (specify their name and number), equipment, and/or drugs, for each author should be given here. (7) Conflicts of interest. (See our Editorial Policies for more details.) In addition, other information about the manuscript, including abstract word count, manuscript word count (excluding figure legends), number of references, and number of figures and tables, must be provided. Please be advised that manuscripts exceeding limits for word count or number of Tables/Figures (See table at the TYPES OF ARTICLES above) may be returned to the authors without peer review.

As *BLOOD CELL THERAPY* follows guidelines defined by the International Committee of Medical Journal Editors (ICMJE, www.icmje.org), please refer to the ICMJE authorship criteria for listing authors.

Abstract

The abstract must be concise and contain 400 words or less. It should accurately describe the outline of the manuscript, including the purpose of the study, basic methods and procedures, main findings, and conclusions. Abbreviations should be avoided, but if necessary, they must be explained at first appearance within the abstract.

Introduction

The introduction should provide only a brief historical background, assuming that the readers are largely familiar with the field. Describe the specific questions or problems that the authors want to address.

Materials and Methods (or Patients and Methods)

Explanation of the experimental methods (including the name and address of the manufacturers of the drugs and equipment) and related references should be sufficient to be reproduced by other researchers. If the Methods part has been published in detail elsewhere, just describe any modifications, along with the appropriate references. In case reports, do not describe any information that may result in the identification of the patient(s).

Authors must declare that procedures or protocols were approved by the Ethical Committee of Human Experimentation, and written informed consent is obtained from all subjects in accordance with the latest version of the Helsinki Declaration. Manuscripts describing animal studies should include a statement giving assurance that the institutional or equivalent committee approved the experiments and the animals received appropriate care from the viewpoint of animal welfare.

BLOOD CELL THERAPY will only consider publishing clinical trials that have been registered in the public trials registry. For more detail, see our Editorial Policies.

Results

The Results section should BRIEFLY present a summary of data presented in figures and/or tables in logical sequence. Units of measured data should be expressed in accordance with SI Units.

Discussion

The data should be interpreted concisely, without repeating in detail data given in the Results section. Focus on new and significant findings of the study along with observations to other relevant studies. The final paragraph should emphasize the main conclusions, and may state any direction for future research.

Acknowledgements (optional)

The following should be briefly described: individuals who provided substantial contributions to the research but did not qualify as authors, all organizational support (e.g. grants, fellowships, chairs; see an example below), and sources of materials (e.g. drugs, reagents, equipment). Refer to the [ICMJE](#) authorship criteria for identifying individuals who should be acknowledged here.

Example: This work was supported by Grant-in-Aid for Scientific Research (grant number) from the Ministry of Education, Culture, Science, Sports, and Technology, Japan (initial of grant holder).

Author's contribution

Authors should carefully consider the list and order of authors before submission. The authorship contribution statement should contain a list of authors' initials and brief explanations of contributions they made in the submitted work.

Example: J.D., and A.B.C. performed experiments; S.H. analyzed results and X.Y.Z. designed the research and wrote the manuscripts.

Conflict of Interest

As *BLOOD CELL THERAPY* adheres to the definition of Conflicts of Interest set up by ICMJE, the Editors ask all authors to submit a completed ICMJE Form for Disclosure of Potential Conflicts of Interest (available at: http://www.icmje.org/coi_disclosure.pdf) at the time of submission. Authors must also disclose any potential conflict of interest in relation to the work, including financial interest such as patent, stock, honorarium for consultation or speech) or free or discounted materials. For details, see our Editorial Policies. If there are no financial conflicts, add the following sentence here: “The authors declare no conflict of interest.”

References

References should be numbered consecutively in the order in which they first appear in the text. Only references essential to the article should be cited. Indicate references by number(s) in superscript. All references cited must be listed at the end of the manuscript. Conference abstracts, unpublished results, and personal communications may be mentioned in the text, in parentheses, with comments such as “Unpublished results” or “Personal communication” with written permission from the source. *BLOOD CELL THERAPY* follows the reference style indicated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.

Examples:

Journal article with more than 6 authors, the names of the first 6 authors must be listed, followed by "et al.":

Okamoto S, Takahashi S, Wakui M, Ishida A, Tanosaki R, Ikeda Y, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. *Br J Haematol.* 1999, 104(3):569-73.

Journal article with 6 or fewer authors, all authors should be listed:

Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplant.* 2009, 44(6):371-4.

* In case of Correspondence, add [letter] just after the title.

Article published electronically ahead of the print version:

Villalobos IB, Takahashi Y, Akatsuka Y, Muramatsu H, Nishio N, Hama A, et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. *Blood.* e-pub ahead of print 1, 2010; doi: 10.1182/blood-2009-11-254284.

Chapter in a book:

Buckner DC, Bensinger W. Preparative regimens. In: Thomas ED, Blume KG, Forman SJ, editors. *Hematopoietic Cell Transplantation*, 2nd ed. Malden, Blackwell Science, 1999, p. 123–134.

The style of in-text citation should be put superscript notation without parenthesis:

···becoming increasing common due to the use of alternative donor sources²⁰

···there have been several reports of experimental MMF use for HSCT^{14 15}

···by immunosuppressive agents such as cyclosporine, tacrolimus, steroids or other therapies¹⁻³

Electronic Book:

Weinberg, Rona Singer, Cryopreservation Techniques and Freezing Solutions, Best Practices in Processing and Storage for Hematopoietic Cell Transplantation, Second Edition, Springer International Publishing, 2018, 63-72, <https://www.springer.com/gp/book/9783319589480>

Web Page:

JDCHCT, The Japanese Data Center for Hematopoietic Cell Transplantation; Activities and Outcomes of Hematopoietic Cell Transplantation in Japan 2018 Summary Slide, 2018, <http://www.jdchct.or.jp/en/data/slide/2018/>, Accessed: 17 November 2019

Journal abbreviations source

Journal names should be abbreviated according to Index Medicus journal abbreviations;

<http://www2.bg.am.poznan.pl/czasopisma/medicus.php?lang=eng>

Figure legends (if applicable)

These should appear after the References section, and comprise a brief title (use **bold** letters) and a description of the figures. The description should be brief and avoid repetition of detailed descriptions presented in Materials and Methods, but must include the number of replicates performed for each experiment(s) shown, if applicable. The result of an appropriate statistical analysis of the data should be indicated with significance (e.g. *P* value) and error bars (e.g. standard deviation). All symbols and abbreviations used should be explained here. Use capital letters (e.g. A, B, C···) for listing in order. Figures must be cited and numbered as they appear in the text. Information about staining methods and original magnification should be given when displaying microphotographs.

Tables (if applicable)

Tables should be numbered consecutively with Arabic numerals. Each table must have a descriptive title on the top and enough information to explain it as a footnote. Type each table on a separate page, in an editable format (Word or Excel) but not in a non-editable image format. They must be cited and numbered as they appear in the text. The significance (e.g. *P* value) of the data should be indicated after the appropriate statistical analysis.

Figures (if applicable)

Figures and images should be numbered and cited as they appear in the text. Figures should not be embedded within the text, but rather uploaded as separate files. Regardless of which application was used to create any electronic artwork, please use “Save as” feature to convert images to one of the following formats: TIFF, JPEG, or EPS. Figures must be original and not have been previously published elsewhere. If authors preparing review articles need to use a previously published figure, the author must apply for written permission from the copyright holder and upload the proof of approval along with the manuscript upon submission.

Supplementary information

Additional information such as figures and tables, detailed Materials and Methods not being included in the main text, videos, or very large data sets, can be published along with the article. The article, however, must be complete, even without the supplementary information. Submitted supplementary files should be in their final version because they will appear exactly as they are submitted, without any editions by the Editorial Office. Be careful not to submit files containing “Track Changes” data added during revisions in Microsoft Office files, since these tracks will appear in the published version. Each supplementary item must be referred to at least once in the main text, just as Figures or Tables. They should be cited, for example: (Supplementary Fig. S1) or (Supplementary Table S1). Supplementary figure must include full legends and tables and should include appropriate captions.

Authors should prepare one single file containing all supplemental data (supplemental methods, supplemental data, supplemental figures, supplemental tables).

Language Editing

Authors who are not native English speakers and who feel their manuscript should be corrected for possible grammatical or spelling errors or for better clarity may try the following step(s) before submission. The authors should have the manuscript reviewed by colleague(s) whose native language is English. They may contract a professional language editing service available in their country. The APBMT Editorial Office may introduce such services, but we will not endorse, nor have any direct involvement with these services, thus the service fee will be charged to the authors directly. Having such services performed does not guarantee acceptance of the manuscript for review or publication. Accepted manuscripts from non-English-speaking countries may be subjected to language editing by the professional service company approved by the APBMT office. The Editorial Board reserves the right to make any corrections to the text in terms of clarity, consistency, integrity, and readability.

Review Process

After submission via our ScholarOne online submission system, authors may monitor the progress of their submission in the review process. Upon receipt, the Editorial Office will perform a technical check to make sure that the submission meets journal standards and includes all required information. If there are any problems, the Editorial Office will return manuscript to authors for corrections. If the manuscript meets the above standards, then the Editor-in-Chief assigns it to an Associate Editor. The Associate Editor invites two or three independent reviewers with expertise in the field to review the

manuscript. The reviewers' reports are submitted through the system to the Associate Editor, who recommends a decision on the manuscript to the Editor-in-Chief. The Editor-in-Chief then changes or approves the editor draft decision letter, and sends the final decision to the corresponding author by e-mail. In case of major/minor revisions, the author can submit a revision by a predetermined deadline. Upon submission of the revised manuscript, the author should describe in detail his/her responses to each point one by one raised by the reviewers in the field of author's response. Besides, all changes should be highlighted in red (or underlined or color-marked) so that each reviewer can follow the changes. If the final decision is to reject the manuscript, the author cannot resubmit. If the final decision is to accept it for publication, the Editorial Office sends the accepted manuscript to the publisher for copyediting and typesetting.

Manuscript Production

After acceptance, *BLOOD CELL THERAPY* does not use the online system during the production stage. Page proofs will be sent via email to the corresponding author as an attached PDF file.

Proof corrections should be returned within 72 hours of receipt. Extensive alterations cannot be made at this stage. Each article will be assigned a DOI (Digital Object Identifier), so that it can be identified by this unique number thereafter. The final version of the proof is official and published online in advance of the scheduled online publication. If the authors plan to do a press release for the accepted paper, the embargo will be lifted at the time of advanced online publication.

Costs

Submission fee:

The Submission fee will be charged when the manuscript is subjected to peer review.

Publication fee:

If the manuscript is accepted, APBMT charges a publication fee for each manuscript.

Offprints:

BLOOD CELL THERAPY does not issue print journals. However, offprints produced from a PDF version of the article may be ordered by use of the Offprint ordering form provided by the Editorial Office.

Author inquiries

For inquiries related to submission requirements, please contact our Editorial Office.

Minako Iida, Yukari Nakao (APBMT Secretariat office, Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University, Nagakute, Aichi, Japan)

E-mail: bcteb"at"apbmt.org

TEL: +81-561-62-3311(Ext.12375)

FAX: +81-561-61-3180

©Copyright 2017 APBMT | <http://www.apbmt.org>

Editorial Policies

Peer Review

Manuscripts sent out for peer review are evaluated by at least two or three independent reviewers with expertise in the field. Authors are allowed to suggest preferred reviewers to evaluate their manuscript, and also non-preferred reviewers to be excluded if a compelling reason is sufficiently provided.

However, no guarantee is given that the editors will include or exclude those suggested individuals. A reviewer may decline the invitation, especially when a potential conflict of interest with the author(s) could be present. Note that only manuscripts that are likely to meet our scope are sent for review. The Editorial Office does not reveal reviewers' identities to authors to avoid any author's attempt to contact reviewers directly. Selected reviewers must keep the manuscript and adjacent materials confidential. If reviewers need help reviewing the manuscript from a colleague, confidentiality must be strictly secured. Reviewers are expected to respond promptly to requests to review, and to submit reviews within the time agreed. Reviewers' comments should be constructive, honest, and polite. The reviewers' reports (provide names if the review was assisted by colleagues) are submitted to the Associate Editor, who recommends a decision on the manuscript to the Editor-in-Chief. If inappropriate reviews are received, either the Associate Editor or Editor-in-Chief has the right to ignore and/or find a replacement for them. Authors are informed of the final decision by e-mail, with comments from reviewers and Editors. The types of decisions are as follows: Accept (may require editorial revisions), Minor Revision, Major Revision, and Reject. If the final decision is to reject, the author cannot resubmit. Throughout the process, any details about submitted manuscripts are kept confidential.

Clinical Trials

BLOOD CELL THERAPY will only consider publishing clinical trials that have been registered in a public trials registry at or before the time of the first patient's enrollment. As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. Health-related interventions are those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes. The ICMJE site also states that the purpose of clinical trial registration is to prevent selective publication and selective reporting of research outcomes, to prevent unnecessary duplication of research efforts, to help patients and the public know what trials are planned or ongoing into which they might want to enroll, and to help give ethics review boards considering approval of new studies a view of similar work and data relevant to the research they are reviewing. In this regard, secondary data analyses of primary clinical trials should not be registered as separate clinical trials, but instead should reference the trial registration number of the primary trial. In addition, authors must declare that the procedures or protocols were approved by the Ethical Committee of Human Experimentation (provide the name of

committee that reviewed the related research and approval number, if applicable), and written informed consent is obtained from all subjects in accordance with the latest version of the Helsinki Declaration. *BLOOD CELL THERAPY* encourages authors to follow Randomized Controlled Trials by adhering to the CONSORT statement (<http://www.consort-statement.org>) for randomized trials, STROBE for observational studies (<http://strobe-statement.org>), and PRISMA for systematic reviews and meta-analyses (<http://prisma-statement.org>).

Human and Other Animal Experiments

Manuscripts describing animal studies should include a statement giving assurance that the institutional or equivalent committee approved the experiments, and the animals received appropriate care from the viewpoint of animal welfare. When using animal models, the precise genotype, strain, source, number of backcrosses, sex, and age of animals must be provided. Authors are encouraged to follow the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (<https://www.nc3rs.org.uk/arrive-guidelines>).

Conflicts of Interest

As *BLOOD CELL THERAPY* adheres to the definition of Conflicts of Interest set up by ICMJE, the Editors ask all authors to submit a completed ICMJE Form for Disclosure of Potential Conflicts of Interest (available at: http://www.icmje.org/coi_disclosure.pdf) at the time of submission. Do not submit the form to ICMJE. For Mac users, please make sure the form does not open with the Mac Preview application. If necessary, information on potential conflict(s) of interest may be disclosed to reviewers. Authors also must disclose any potential conflict of interest in relation to the work, including financial interests (such as patent, stock, or honorarium for consultation or speech) or free or discounted materials. Only the existence of COI does not necessarily preclude your submitted work from publication. Rather, disclosure of any potential COI is essential for transparency and to avoid any suspicion.

If there are no financial conflicts, add the following sentence here: “The authors declare no conflict of interest.”

Editors (Editor-in-Chief and Associate Editors) are obliged to disclose and annually update any potential Conflict of Interest to *BLOOD CELL THERAPY* for keeping the high integrity and transparency of the review process of the journal. Reviewers should declare their conflicts of interest and recuse themselves from the peer-review process if a conflict exists.

Authorship

As *BLOOD CELL THERAPY* follows the guideline defined by the International Committee of Medical Journal Editors (ICMJE, www.icmje.org), please refer to the ICMJE authorship criteria for listing authors. As stated on the ICMJE site, authorship not only confers credit and has important academic, social, and financial implications, but also implies responsibility and accountability for published work. This is why distinguishing authors from other contributors is critical. For this purpose, authors are

encouraged to carefully read the criteria “Defining the Role of Authors and Contributors” (See the embedded link at <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>) and provide the following information in “Acknowledgement” and “Author’s contribution” after the main text of the manuscript.

Acknowledgement

The following should be briefly described: individuals who provided substantial contributions to the research but did not qualify as authors, all organizational support (e.g. grants, fellowships, chairs; see an example below), and sources of materials (e.g. drugs, reagents, equipment).

Example: This work was supported by Grant-in-Aid for Scientific Research (grant number) from the Ministry of Education, Culture, Science, Sports, and Technology, Japan (initial of grant holder).

Author’s contribution

Authors should carefully consider the list and order of authors before submission. The authorship contribution statement should contain a list of authors’ initials and brief explanations of contributions each made in the submitted work.

Example: J.D., and A.B.C. performed experiments; S.H. analyzed results and X.Y.Z. designed the research and wrote the manuscripts.

Duplicate Publication

Manuscripts (or its essential substance) must be original and has not been published other than as an abstract in any language or format and has not been submitted elsewhere for print or electronic publication consideration. This rule also applies to non-English language publications. Any manuscripts that might be regarded as duplicate publications of the same or very similar work must be avoided.

Rather, any such work should be referred to and referenced in the current manuscript. To facilitate this understanding, copies of such work should be also uploaded on submission. This recommendation does not prevent considering a complete report that follows publication of a preliminary report, such as a letter to the editor, an abstract, or a poster displayed at a scientific meeting. In addition, secondary publication of material published in other journals or online may be justifiable and beneficial, especially when intended to disseminate important information to the widest possible audience. Conditions where secondary publication for various other reasons may also be justifiable are listed under “Acceptable Secondary Publication” at the ICMJE website (See embedded link at <http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/overlapping-publications.html>).

Authors who attempt duplicate publication without such notification should expect prompt rejection of the submitted manuscript. If the editor was not aware of the violations and the article has already been published, then the article might warrant retraction with or without the author’s explanation or approval.

BLOOD CELL THERAPY encourages authors to consult the COPE flowcharts (<http://publicationethics.org/resources/flowcharts>) for details.

Permissions

If a Figure or a Table has been published previously, acknowledge the original source and obtain written permission from the copyright holder to reproduce it. Permission is required irrespective of authorship or publisher, except for documents in the public domain. Note that these rules also apply to authors of (invited) review articles. Information from manuscripts submitted, but not accepted, should be cited in the text as “unpublished observations” with written permission from the source. For scientific articles, obtain written permission and confirmation of accuracy from the source for a personal communication.

Research Data Policy

Authors are encouraged to deposit their datasets (e.g. gene expression microarrays, SNP arrays, and high-throughput sequencing) into relevant public repositories or present all of them in the main manuscript or in the supplementary files, if possible. Authors should state information such as data set name and repository name in their manuscript. Alternatively, any datasets or other relevant information must be available upon request. It is always good practice for authors to keep the primary data and associated procedures used to conclude the reported research for at least 10 years.

In addition to obtained datasets, information about the methods or analytical design taken to obtain data is also fully described in the manuscript and maintained for transparency and reproducibility of the published results.

Plagiarism and Fabrication/Correction and Retraction

Plagiarism refers to the misconduct of passing off someone else's work as one's own original work without providing credit to the original source. Fabrication refers to the misconduct of falsifying data or manipulating images to deceive others. Reuse of a limited part of the introduction or methods from an earlier paper may be relatively acceptable. When scientific misconduct is alleged, or such concerns are raised in submitted manuscripts or published articles, the Editors will conduct an investigation by following the COPE guideline (<https://publicationethics.org/resources/guidelines>). If plagiarism is proven during review, the manuscript will be promptly rejected. If plagiarism is proven after publication, the article may be formally retracted or subjected to correction or errata, depending upon the circumstances. In case of proven scientific fraud, the Editors will also contact the appropriate official(s) at the authors' institution(s) and/or funding agencies, if necessary.

Copyright Transfer Agreement (CTA)

This is a sample of the Copyright Transfer Agreement (CTA) that the corresponding author will be required to complete through online ScholarOne Manuscripts system if your paper is submitted for publication. An NIH or other U.S. federal employee needs to document his/her status and thus may be exempt from transferring copyright depending on the degree of his/her contribution. The printed copy of this page should be used as a formal CTA form.

In order to proceed to the editing and publishing process and enable the Society to disseminate your manuscript, the corresponding author, on behalf of all authors, will be required to complete the electronic

Copyright Transfer Agreement (CTA) and provide an electronic signature in the window. Manuscripts will not be pre-published or sent for production until the corresponding author provides an electronic signature.

1. I hereby transfer and assign all copyrights in and to the manuscript mentioned above (called the Contribution hereafter) in all forms, now or hereafter known, to the Asia-Pacific Blood and Marrow Transplantation Group (APBMT), effective when the Contribution is accepted for publication in Blood Cell Therapy, the official journal of Asia-Pacific Blood and Marrow Transplantation Group.

2. I understand that if and when the manuscript is accepted for publication in Blood Cell Therapy, it will be pre-published online as an Online First paper, unless otherwise specified. I acknowledge that the Online First papers undergo full peer review; however, prior to any editorial preparation, including copyediting, typesetting, and proofreading for a final print and online version, the corresponding author is responsible for its accuracy as an Online First paper.

3. I warrant that the manuscript is original and has not been published or submitted for publication simultaneously to more than one journal; and that I have acknowledged the original source and obtained written permission from the copyright holder to use any previously published textual materials, Figures, or Tables. I agree that it is my responsibility to pay any fees charged for permissions.

4. As an author, I retain the following nonexclusive copyrights, to be exercised only after the Contribution has been published in final format in the print version of Blood Cell Therapy.

(1) Reprint the Contribution in my own writing in print.in print forms of my own writing.

(2) Present the Contribution orally in academic meetings.

(3) Use the Contribution for theses and/or dissertation purposes.

(4) Reproduce the Contribution for educational purposes.

(5) Reuse figures and tables in my future works for noncommercial purposes.

(6) Present a copy of the Contribution on my personal and /or departmental websites if a hyperlink to the original site on APBMT web page is provided.

(7) Whenever cited, I will give due credit to the original publication in Blood Cell Therapy

By clicking on the "I agree" button below, the author certifies compliance with the form.

☐ I agree to the COPYRIGHT TRANSFER AGREEMENT as shown above and have obtained written permission from all other Contributors to execute this Agreement on their behalf.

----- or -----

☐ I confirm US Federal Government Employment:

Date:

Contributor's signature (type name here):

Guide for Reviewers

All submitted manuscripts are initially assessed by the Editor-in-chief for suitability to our journal. Afterwards, a peer review is conducted to have the submitted manuscript be assessed by experts in the relevant research field. In order to review the manuscript in a manner that is appropriate and fair, there are three very important things to consider before reviewers accept the invitation to the peer review process:

1) Conflict of interests

Presence of a conflict of interest does not necessarily disqualify you as a reviewer, but it is important to declare any potential conflict of interest in the “Blind comments to the Editor” box in the on-line reviewing system. If you have any concerns, do not hesitate to contact the editorial office.

2) Competence: Your field of expertise

If you are not confident that your field of expertise can cover the content of the manuscript for review, contact the editorial office as soon as possible. If you have an alternative reviewer whose expertise you believe will match the manuscript, please let us know.

3) Confidentiality

All submitted manuscripts, including supplements, must be handled confidentially. Reviewers must not disclose content to anyone until the manuscript is published. Reviewers must not retain a copy for any kind of personal purpose; all copies must be destroyed in an appropriate manner immediately after the review process.

General attitude for review

Reviewers are expected to promptly submit their reviews within the predetermined deadline. First, please evaluate whether the submitted manuscript meets the scope of *Blood Cell Therapy*. Always bear in mind that the reviewer should provide constructive, objective, honest, helpful, and polite comments so that the author will be able to improve their manuscript. Finally, reviewers are expected to refrain from making hostile or derogatory comments.


The peer review process

1) Use of the on-line review system

Blood Cell Therapy has adopted the ScholarOne online system. Information for reviewers on the use of the system can be found at:

<http://mchelp.manuscriptcentral.com/gethelpnow/training/reviewer/>

Candidate reviewers that are invited by e-mail are asked to select the appropriate hyperlink for sending their response to the journal (please see the Workflow below). If you select the “Agreed” hyperlink, you will receive an additional e-mail that contains a link to your reviewer center. Thereafter, follow the guidance that appears in the web page. If you have any further questions, please see the web page in the above link for more detailed information.



2) Scoring the assigned manuscripts

Does the manuscript contain new and significant information to justify publication?

Is the problem significant and concisely stated?

Are the interpretations and conclusions justified by the results?

Is adequate reference made to other work in the field?

Is the language acceptable?

Yes. No. Not Applicable

Please state any conflict(s) of interest that you have in relation to the review of this paper (state “none” if this is not applicable).

After a successful log-in, a score sheet will be opened. There you will find categories for rating, a “Recommendation field,” “Confidential Comments to the Associate Editor,” and “Comments to the Author.”

At the top, you are asked to score the submitted manuscript from the following five points of view: “Novelty,” “Concise and clear presentations,” “Justification of conclusions,” “Adequate references,” and “Quality of English writing,” by using the following ratings: Yes, No, and Poor. For more information, please see below – “In addition, attention should be paid to each part of the manuscript” –.

Next, you are asked to disclose your potential conflict of interest.

Third, you are asked to score the submitted manuscript from the following four points of view: “Importance,” “Quality,” “Originality,” and “Overall,” by using the following ratings: Excellent, Good, Average, Below Average, and Poor.

- Importance: Articles of importance must help our readers (and potential general readers) to update their knowledge, to make better clinical decisions in their practices, and to inspire readers to raise the next research questions.
- Quality: Articles that are of good quality refer to reports of research that have been conducted with careful and logical design, offer objective analyses with sound statistics, and are verifiable and replicable by others. Quality also consists of the adequate use of written English that clearly informs the reader of what the author intended to convey.
- Originality: Articles with originality must include findings that are sufficiently novel to what has been shown in previously published literature.
- Overall: Comprehensive evaluation with the above factors considered, alongside others.

Next, reviewers are encouraged to convey their own decision to the editors by selecting what is deemed appropriate from the following: Accept, Minor Revision, Major Revision, and Reject.

3) Describing your comments and submission of your total evaluation

Finally, reviewers are asked to report their comments using the Comments box. We use the single-blind review system where reviewers can recognize the author of the manuscript while remaining anonymous. The outline of this process is listed as follows:

- “Confidential Comments to the Editor” box

If you have confidential comments for the editor, write them in this box.

Examples of comments could be:

- (i) Any suspicion of ethical issues such as plagiarism, duplicate submission, unrevealed conflict of interest related to authors, human subjects, or animal welfare.
- (ii) Reason for your recommendation (accept, major/minor revision, reject).

(iii) Concerns regarding the authorship, the experimental design, wrong statistical tests, or violation of law.

- Comments to the author

(i) It is advisable to first summarize the main findings as addressed in the manuscript, which helps the editor(s) understand the key points of the manuscript and helps the authors to understand the reviewer's interests and concerns to the manuscript. However, refrain from the provision of a statement of recommendation for acceptance or rejection.

(ii) Divide your comments into major/essential and minor ones, where the former is critical for acceptance of the manuscript.

(iii) Organize your comments by numbering.

(iv) Cite relevant prior work to your comments to support your criticism.

(v) Refer to the relevant guidelines (clinical trials, statistical analysis, or microarray experiments, etc.) that may affect the contents.

- In addition, attention should be paid to each part of the manuscript, as below:

(i) Title: Is it informative enough to indicate the contents?

(ii) Abstract: Is it well-organized and summarized within the word limits in accordance with the type of the article?

(iii) Introduction: Is it concise, and does it clearly provide the purpose and the rational of the study as based on previous reports? Does the research article convey the authors' hypothesis or the concept of the study?

(iv) Materials and Methods: Do they provide sufficient information clearly so that the results can be repeated/reproduced by other researchers? If necessary, further information can be requested as supplementary data.

(v) Results: Are they clearly presented following a short introduction and description of the methods used? Are figures and/or tables necessary and sufficient? Is each figure self-explanatory with sufficient captions?

(vi) Discussion: Is it concise enough and relevant to their results? Has the hypothesis or concept been justified by the data obtained? Is the conclusion logical and sound? Are unexpected results fully accounted for by the authors? Do they present the merits and limitations of their study for future studies?

(vii) References: Does the reference list adhere to our journal requirements?

4) Editor's final decision

The Editor-in-chief makes the final decision, taking into consideration the reviewers' comments and the Associate Editor's suggestions. The decision letter will be sent to the corresponding author, reviewers, and Associate Editor(s) via an e-mail from the online system.

List of the accepted articles (As of August 31, 2019)

Original Article

Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase hematopoietic cell transplantation

Noriyasu Fukushima^{1,2,3}, Satoshi Tomiyasu², Yoshinori Ujiz², Masako Yokoo³, Takero Shindo³, Yasushi Kubota³,

Toshihiko Ando³, Kensuke Kojima³, Eisaburo Sueoka⁴, Tatsuo Ichinohe¹, Shinya Kimura³

¹Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. ²Department of Medical Science Technology, School of Health Sciences at Fukuoka,

International University of Health and Welfare, Okawa, Japan ³Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. ⁴Department of Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Blood Cell Therapy Vol.1 Issue.1 No.1 Pages 1-8

Submitted: December 19, 2017 Accepted: July 7, 2018 Published online: August 29, 2018

DOI:<https://doi.org/10.31547/bct-2017-002>

Review Article

Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia

Sung-Eun Lee and Jong Wook Lee

Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Blood Cell Therapy Vol.1 Issue.1 No.2 Pages 9-17

Submitted: March 6, 2018 Accepted: May 19, 2018 Published online: August 29, 2018

DOI:<https://doi.org/10.31547/bct-2018-001>

Review Article

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy

Yingying Yang, Yongxian Hu, Jiasheng Wang, He Huang

Zhejiang University School of Medicine First Affiliated Hospital

Blood Cell Therapy Vol.1 Issue.1 No.3 Pages 18-27

Submitted: April 12, 2018 Accepted: July 7, 2018 Published online: August 29, 2018

DOI:<https://doi.org/10.31547/bct-2018-003>

Case Report

Primary CNS post-transplant lymphoproliferative disorder following haplo- identical HSCT using post-transplant high-dose cyclophosphamide

Masako Toyosaki¹, Makoto Onizuka¹, Jun Amaki¹, Sawako Shiraiwa¹, Yasuyuki Aoyama¹, Shinichiro Machida¹, Hidetsugu Kawai¹, Hiromichi Murayama¹, Daisuke Ogiya¹, Keiko Matsui¹, Shohei Kawakami¹, Kaito Harada¹, Yusuke Kondo², Kenichi Hirabayashi², Naoya Nakamura², Yoshiaki Ogawa¹, Hiroshi Kawada¹, Kiyoshi Ando¹

¹Division of Hematology and Oncology, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, ² Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan

Blood Cell Therapy Vol.2 Issue.1 No.1 Pages 1-4

Submitted: May 8, 2018 Accepted: August 9, 2018 Published online: October 26, 2018

DOI:<https://doi.org/10.31547/bct-2018-004>

Case Report

Successful allogeneic peripheral blood stem cell transplantation for an aggressive variant of T-cell large granular-lymphocyte leukemia: A case report

Kazuhito Suzuki^{1,2}, Kaichi Nishiwaki^{1,2}, Jiro Minami², Hidekazu Masuoka^{1,2}, Mitsuji Katori^{1,2}, Hiroki Yokoyama^{1,2}, Hideki Uryu^{1,2}, Shingo Yano²

¹Division of Clinical Oncology/Hematology, The Jikei University Kashiwa Hospital

²Division of Clinical Oncology/Hematology, The Jikei University School of Medicine

Blood Cell Therapy Vol.2 Issue.1 No.2 Pages 5-8

Submitted: May 20, 2018 Accepted: September 5, 2018 Published online: October 26, 2018

DOI:<https://doi.org/10.31547/bct-2018-006>

Case Report

Gastric antral vascular ectasia in a pediatric patient with neuroblastoma who underwent tandem stem cell transplantation

Yumiko Sugishita, Shohei Yamamoto, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Kosuke Akiyama, Ryosuke Matsuno, Daisuke Toyama, Keiichi Isoyama

Department of Pediatrics, Showa University Fujigaoka Hospital, Japan

Blood Cell Therapy Vol.2 Issue.1 No.3 Pages 9-11

Submitted: August 24, 2018 Accepted: October 2, 2018 Published online: January 15, 2019

DOI:<https://doi.org/10.31547/bct-2018-007>

Review Article

Autologous hematopoietic stem cell transplant for autoimmune diseases: evolution, evidence of efficacy, and real-world economics

Massey, Jennifer C.^{1,2,3}, Moore, John J.^{2,3,4}, Milliken, Samuel T.⁴, Ma, David D. F.^{2,3,4,5}

¹Department of Neurology, St Vincent's Hospital Sydney, Australia, ²Blood, Stem Cell and Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, Australia, ³St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia, ⁴Department of Haematology and Bone Marrow Transplant, St Vincent's Hospital Sydney, Australia, ⁵Corresponding author

Blood Cell Therapy Vol.2 Issue.2 No.1 Pages 12-21

Submitted: September 14, 2018 Accepted: October 23, 2018 Published online: April 1, 2019

DOI:<https://doi.org/10.31547/bct-2018-009>

Original Article

Kinetics of neutrophil engraftment in allogeneic stem cell transplantation

Akihisa Kawajiri¹, Shigeo Fujii^{1,2}, Yoshihiro Inamoto¹, Saiko Kurosawa¹, Takashi Tanaka¹, Ayumu Ito¹, Keiji Okinaka¹, Sung-Won Kim¹, Takahiro Fukuda¹

¹Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

²Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

Blood Cell Therapy Vol.2 Issue.2 No.2 Pages 22-30

Submitted: October 20, 2018 Accepted: January 23, 2019 Published online: April 1, 2019

DOI:<https://doi.org/10.31547/bct-2018-011>

Short Communication

A decade of excellent transplant survival in children with inherited metabolic diseases: A report from a single metabolic transplant centre in Europe

Su Han Lum¹, Andrew Willi¹, Heather J Church², Jean Mercer², Karen L Tylee², Kay Poulton³, Wendy Odgen⁴, Helena Lee³, Alison Logan³, Mary Coussons¹, Tasneem Khalid⁵, Denise Bonney¹, Stewart Rust⁶, Prashant Hiwarkar¹, Simon A Jones², Robert F Wynn¹

¹Department of Pediatric Blood and Marrow Transplant, Royal Manchester Children's Hospital, UK, ²Manchester Center for Genomic Medicine, St Mary's Hospital, Manchester, UK, ³Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK, ⁴Therapeutic Stem Cell Laboratory, Royal Manchester Children's Hospital, Manchester, UK, ⁵Department of Pharmacy, Royal Manchester Children's Hospital, Manchester, UK, ⁶Pediatric Psychosocial Department, Royal Manchester Children's Hospital, Manchester, UK

Blood Cell Therapy Vol.2 Issue.2 No.3 Pages 31-35

Submitted: October 23, 2018 Accepted: February 8, 2019 Published online: May 10, 2019

DOI:<https://doi.org/10.31547/bct-2018-012>

Case Report

Role of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a report of 2 unique cases

Yadanar Lwin¹, David Ma^{1,2}

¹Department of Haematology and BM Transplant, St Vincent's Hospital Sydney, NSW, Australia, ²St Vincent's Clinical School, Faculty of Medicine, the University of New South Wales

Blood Cell Therapy Vol.2 Issue.3 No.1 Pages 36-38

Submitted: March 25, 2019 Accepted: April 5, 2019 Published online: June 7, 2019

DOI:<https://doi.org/10.31547/bct-2019-001>

Original Article

Predictors of parental distress during acute phase of pediatric hematopoietic stem cell transplantation in Japan: A multicenter prospective study

Shohei Nakajima¹, Ami Setoyama¹, Iori Sato¹, Tomoko Fukuchi², Harumi Tanaka², Masami Inoue³, Kentaro Watanabe⁴, Katsuyoshi Koh⁴, Junko Takita⁵, Mika Tokuyama⁶, Kenichiro Watanabe⁶, Kiyoko Kamibepu¹

¹Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Nursing, Osaka Women's and Children's Hospital, Osaka, Japan, ³Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan, ⁴Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, ⁵Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan, ⁶Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.

Blood Cell Therapy Vol.2 Issue.3 No.2 Pages 39-49

Submitted: October 18, 2018 Accepted: April 15, 2019 Published online: June 18, 2019

DOI:<https://doi.org/10.31547/bct-2018-010>

Survey Report

Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka

P Abeyasinghe¹, L Morawaka², S Gunasekara¹, S Suresh¹, PWDCC Jayathilake¹, PHSP Udara¹, PPR Siriwardena¹, S Milliken³, J Moore³, DDF Ma³

¹National Cancer Institute, Sri Lanka, ²National Blood Transfusion Service, Sri Lanka, ³Department of Haematology and BM Transplantation, St. Vincent's Hospital Sydney, NSW, Australia

Blood Cell Therapy Vol.2 Issue.4 No.1 Pages 50-53

Submitted: May 29, 2019 Accepted: August 25, 2019 Published online: November 25, 2019

DOI:<https://doi.org/10.31547/bct-2019-007>

Appendix

Offering Delta Mileage to medical professionals in emerging countries/regions to support their journeys in the Asia-Pacific region by the Japanese Marrow Donor Registry Promotion Conference (JMDRPC)

[Background and aims of this project]

APBMT encourages medical professionals in emerging countries/regions to obtain knowledge and skills regarding Hematopoietic Stem Cell Transplantation by attending international congresses which will further contribute to the development of such technologies in their countries. However, costly travel expenses are an obstacle that prevents young medical professionals from participating.

The Japanese Marrow Donor Registry Promotion Conference (JMDRPC) possesses miles donated by contributors who use Delta Airlines through the Sky Wish Charity program. The aim of this project is to utilize these miles to support the travel expenses of medical professionals from emerging countries towards the improvement of hematopoietic cell transplantation; thus, this project will expand opportunities for patients in emerging countries to receive transplants.

[Targets of this support must]

- Have a medical license (doctors, nurses, etc.)
- Have been confirmed to attend a conference related to HSCT in the Asia-Pacific region.
- Be judged as adequate recipients by the judging board of this project

[About the ticket offer]

- Economy class round-trip ticket that is in the service of Delta Airlines and affiliated airlines (Appendix: Sky team alliance)
- It is possible to travel to major cities in the world, though a transit airport might be designated. In addition, departure (in the case of return flights) might be from a domestic hub airport rather than a local airport.
- Fuel surcharge fees and airport usage fees other than the air ticket shall be borne by the applicant (the traveler himself/herself). After determining the flight number/amount, fees are paid to the account of the Japanese Marrow Donor Registry Promotion Conference (JMDRPC).
- Due to the limited number of mileage tickets available, the number of days between flights might increase to more than the traveler originally considered.

[How to apply]

- The applicant must be from an APBMT participating country/region.
- Applicants must complete the application form on the web.

Requirements:

1. Name, occupation, institution, copy of passport
2. Schedule of outbound flight; departure date, departure airport, arrival airport
3. Schedule of return flight; departure date, departure airport, arrival airport

[Responsibility to report]

- Applicants who receive benefits through support from this project are required to submit a small report to APBMT within one month after returning.
- An overview of the report will be included in the publications of the Japanese Marrow Donor Registry Promotion Conference (JMDRPC) and APBMT (Annual Report).

[Contact]

Minako Iida, Yukari Nakao (APBMT Secretariat Office)

Department of Promotion for Blood and Marrow Transplantation

Aichi Medical University, School of Medicine

1-1, Yazakokarimata, Nagakute, Aichi, 480-1195, Japan

Tel: +81-561-62-3311 (Ext.12375) Fax: +81-561-61-3180

Email address: miida@aichi-med-u.ac.jp

SkyTeam member airlines

Aeroflot	Mandarin Airlines	KLM Cityhopper
Aerolineas Argentinas	China Eastern Airlines	KOREAN AIR
Austral Lineas Aereas	Shanghai Aielines	Jin Air
Aeromexico	China Southern Airlines	Middle East Airlines
Aeromexico Connect	Czech Airlines	Saudia
Air Europa	Delta Air Lines	TAROM
Air France	Delta Connection, Delta Shuttle	Vietnam Airlines
Alitalia	Garuda Indonesia	XiamenAir
Alitalia CityLiner	Kenya Airways	
China Airlines	KLM	

Beneficiaries in 2018 and 2019

2018	Malaysia	Bee Ping Chong
	Mongolia	Batsukh Khishigjargal
	Myanmar	Aye Aye Gyi
2019	India	Uday Yanamandra
	Malaysia	Nur Adila bt Anuar
	Malaysia	Norashikin binti Saidon
	Malaysia	Normala binti Arshad
	Malaysia	Zulaili yunus
	Mongolia	Myadagsuren Sukhbaatar

Associate members



Banner contributions



Bristol-Myers Squibb



MSD株式会社 www.msd.co.jp



APBMT Annual Report Fiscal 2018

APBMT officers

President

Shinichio Okamoto
Department of Hematology
Keio University
35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
Tel: +81 3 3335 1221
okamoto@a7.keio.jp

Secretariat office

E-mail: office@apbmt.org

Website: <http://www.apbmt.org>

Department of Promotion for Blood and Marrow Transplantation
Aichi Medical University School of Medicine
1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan
Tel: +81 561 62 3311 (Ext. 12375) Fax: +81 561 61 3180

Minako Iida
miida@aichi-med-u.ac.jp

Yukari Nakao
yukari-nakao@aichi-med-u.ac.jp

Hiroe Namizaki
namizaki@aichi-med-u.ac.jp

Yoshihisa Koder (Past-President)
ykoder@river.ocn.ne.jp



